ERA June 1 - 2026 Supporting materials FOCUSED ORAL PRESENTATION: Effect of Sibeprenlimab on eGFR in Adults With IgA Nephropathy: A Prespecified Interim Analysis of the VISIONARY Phase 3 Trial
